Skip to main content

Advertisement

SpringerLink
Log in

Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Polo-like kinase 2 (SNK/PLK2), a transcriptional target for wild-type p53 and is hypermethylated in a high percentage of multiple myeloma and B cell lymphomas patients. Given these data, we sought to study the methylation status of the specific gene in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), and to correlate it with clinical and genetic features. Using methylation-specific PCR MSP, we analyzed the methylation profile of 45 cases of AML and 43 cases of MDS. We also studied the distribution of MTHFR A1298C and MTHFR C677T polymorphisms and FLT3 mutations in AML patients and correlated the results with hypermethylation in the SNK/PLK2 CpG island. The SNK/PLK2 CpG island was hypermethylated in 68.9% and 88.4% of AML and MDS cases, respectively. Cases with hypermethylation had a trend towards more favorable overall survival (OS). There was no association between different MTHFR genotypes and susceptibility to develop AML. SNK/PLK2 hypermethylation combined with the MTHFR AA1298 genotype was associated with a tendency for a better OS. Similarly, patients with SNK/PLK2 hypermethylation combined with the MTHFR CT677 polymorphism had a better OS (HR = 0.34; p = 0.017). SNK/PLK2 methylation associated with unmutated FLT3 cases had a trend for better OS compared to patients with mutated FLT3 gene. SNK/PLK2 is a novel epigenetically regulated gene in AML and MDS, and methylation occurs at high frequency in both diseases. As such, SNK/PLK2 could represent a potential pathogenetic factor, although additional studies are necessary to verify its exact role in disease pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358:1148–1159

    Article  PubMed  CAS  Google Scholar 

  2. Rush LJ, Plass C (2002) Alterations of DNA methylation in hematologic malignancies. Cancer Lett 185:1–12

    Article  PubMed  CAS  Google Scholar 

  3. Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2(Suppl 1):S4–S11

    Article  PubMed  CAS  Google Scholar 

  4. Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597–610

    Article  PubMed  CAS  Google Scholar 

  5. Rice KL, Hormaeche I, Licht JD (2007) Epigenetic regulation of normal and malignant hematopoiesis. Oncogene 26:6697–6714

    Article  PubMed  CAS  Google Scholar 

  6. Boultwood J, Wainscoat JS (2007) Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 138:3–11

    Article  PubMed  CAS  Google Scholar 

  7. Donaldson MM, Tavares AA, Hagan IM, Nigg EA, Glover DM (2001) The mitotic roles of Polo-like kinase. J Cell Sci 114:2357–2358

    PubMed  CAS  Google Scholar 

  8. Smith P, Syed N, Crook T (2006) Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3. Cell Cycle 5:1262–1264

    Article  PubMed  CAS  Google Scholar 

  9. van de Weerdt BC, Medema RH (2006) Polo-like kinases: a team in control of the division. Cell Cycle 5:853–864

    Article  PubMed  Google Scholar 

  10. Cizmecioglu O, Warnke S, Arnold M, Duensing S, Hoffmann I (2008) Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle 7:3548–3555

    Article  PubMed  CAS  Google Scholar 

  11. Winkles JA, Alberts GF (2005) Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24:260–266

    Article  PubMed  CAS  Google Scholar 

  12. Ma S, Charron J, Erikson RL (2003) Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 23:6936–6943

    Article  PubMed  CAS  Google Scholar 

  13. Burns TF, Fei P, Scata KA, Dicker DT, El-Deiry WS (2003) Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23:5556–5571

    Article  PubMed  CAS  Google Scholar 

  14. Eckerdt F, Yuan J, Strebhardt K (2005) Polo-like kinases and oncogenesis. Oncogene 24:267–276

    Article  PubMed  CAS  Google Scholar 

  15. Krämer A, Neben K, Ho AD (2005) Centrosome aberrations in hematological malignancies. Cell Biol Int 29:375–383

    Article  PubMed  Google Scholar 

  16. Matthew EM, Hart LS, Astrinidis A, Navaraj A, Dolloff NG, Dicker DT, Henske EP, El-Deiry WS (2009) The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle 8:4168–4175

    Article  PubMed  CAS  Google Scholar 

  17. Hatzimichael E, Dasoula A, Benetatos L, Syed N, Dranitsaris G, Crook T, Bourantas K (2010) Study of specific genetic and epigenetic variables in multiple myeloma. Leuk Lymphoma 51:2270–2274

    Article  PubMed  CAS  Google Scholar 

  18. Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, O’Nions J, Allday M, Hoffmann I, Crawford D, Griffin B, Farrell PJ, Crook T (2006) Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107:250–256

    Article  PubMed  CAS  Google Scholar 

  19. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951

    Article  PubMed  CAS  Google Scholar 

  20. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilstöcker M, Rüter B, Sperr WR, Stauder R, Wells DA (2007) Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 31:727–736

    Article  PubMed  Google Scholar 

  21. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510

    Article  PubMed  Google Scholar 

  22. Fröhling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol 23:6285–6295

    Article  PubMed  Google Scholar 

  23. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA, Morgan G (1999) Polymorphisms in the methylenetetrahydrofolatereductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 96:12810–12815

    Article  PubMed  CAS  Google Scholar 

  24. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642–4649

    Article  PubMed  Google Scholar 

  25. Nimer SD (2008) Myelodysplastic syndromes. Blood 111:4841–4851

    Article  PubMed  CAS  Google Scholar 

  26. Tefferi A, Vardiman JW (2009) Myelodysplastic syndromes. N Engl J Med 361:1872–1885

    Article  PubMed  CAS  Google Scholar 

  27. Renneville A, Roumier C, Biggio V, Nibourel O, Boissel N, Fenaux P, Preudhomme C (2008) Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia 22:915–931

    Article  PubMed  CAS  Google Scholar 

  28. Esteller M (2003) Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109:80–88

    Article  PubMed  CAS  Google Scholar 

  29. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Löwenberg B, Delwel R, Melnick A (2010) DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13–27

    Article  PubMed  CAS  Google Scholar 

  30. Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP (2008) Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:1366–1373

    Article  PubMed  CAS  Google Scholar 

  31. Deneberg S, Grövdal M, Karimi M, Jansson M, Nahi H, Corbacioglu A, Gaidzik V, Döhner K, Paul C, Ekström TJ, Hellström-Lindberg E, Lehmann S (2010) Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia. Leukemia 24:932–941

    Article  PubMed  CAS  Google Scholar 

  32. Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O’Keefe C, Sekeres M, Saunthararajah Y, Maciejewski JP (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113:1315–1325

    Article  PubMed  CAS  Google Scholar 

  33. Wu SJ, Yao M, Chou WC, Tang JL, Chen CY, Ko BS, Huang SY, Tsay W, Chen YC, Shen MC, Wang CH, Yeh YC, Tien HF (2006) Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 135:317–323

    Article  PubMed  CAS  Google Scholar 

  34. Potapova A, Hasemeier B, Römermann D, Metzig K, Göhring G, Schlegelberger B, Länger F, Kreipe H, Lehmann U (2010) Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes. Eur J Haematol 84:298–303

    Article  PubMed  CAS  Google Scholar 

  35. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605–613

    Article  PubMed  CAS  Google Scholar 

  36. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054

    Article  PubMed  CAS  Google Scholar 

  37. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U (2008) Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299:2423–2436

    Article  PubMed  CAS  Google Scholar 

  38. Kim HN, Kim YK, Lee IK, Yang DH, Lee JJ, Shin MH, Park KS, Choi JS, Park MR, Jo DY, Won JH, Kwak JY, Kim HJ (2009) Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res 33:82–87

    Article  PubMed  CAS  Google Scholar 

  39. Guillem VM, Collado M, Terol MJ, Calasanz MJ, Esteve J, Gonzalez M, Sanzo C, Nomdedeu J, Bolufer P, Lluch A, Tormo M (2007) Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia 21:1413–1422

    Article  PubMed  CAS  Google Scholar 

  40. Bolufer P, Collado M, Barragan E, Calasanz MJ, Colomer D, Tormo M, González M, Brunet S, Batlle M, Cervera J, Sanz MA (2007) Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 136:590–596

    Article  PubMed  CAS  Google Scholar 

  41. Meshinchi S, Appelbaum FR (2009) Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 15:4263–4269

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, University Hospital of Ioannina, Niarchos Avenue, 45500, Ioannina, Greece

    Leonidas Benetatos, Aggeliki Dasoula, Eleftheria Hatzimichael, Maria Voukelatou & Konstantinos L. Bourantas

  2. Imperial College, Charing Cross Hospital, London, UK

    Nelofer Syed & Tim Crook

  3. Department of Medical Oncology, Princess Margaret Hospital, Toronto, Canada

    George Dranitsaris

Authors
  1. Leonidas Benetatos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aggeliki Dasoula
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eleftheria Hatzimichael
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nelofer Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Voukelatou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. George Dranitsaris
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Konstantinos L. Bourantas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tim Crook
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonidas Benetatos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benetatos, L., Dasoula, A., Hatzimichael, E. et al. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 90, 1037–1045 (2011). https://doi.org/10.1007/s00277-011-1193-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-011-1193-4

Keywords

Search

Navigation